Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

MASH faced an issue that almost no other sitcom has been able to overcome, but this ended up somehow making the classic ...

Though there are very few characters in MASH who aren't beloved by audiences and critics, these individuals rise to the top ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

This local sensation mashes up pop and rock hits with a full brass section, turning every show into a high-energy singalong.

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

It took a month, but this is the Phillies lineup that was advertised. They pounded the Rays on Wednesday to with their fourth ...